» Articles » PMID: 36946080

Engineered Probiotics As Live Biotherapeutics for Diagnosis and Treatment of Human Diseases

Overview
Publisher Informa Healthcare
Specialty Microbiology
Date 2023 Mar 22
PMID 36946080
Authors
Affiliations
Soon will be listed here.
Abstract

The use of probiotics to regulate the intestinal microbiota to prevent and treat a large number of disorders and diseases has been an international research hotspot. Although conventional probiotics have a certain regulatory role in nutrient metabolism, inhibiting pathogens, inducing immune regulation, and maintaining intestinal epithelial barrier function, they are unable to treat certain diseases. In recent years, aided by the continuous development of synthetic biology, engineering probiotics with desired characteristics and functionalities to benefit human health has made significant progress. In this article, we summarise the mechanism of action of conventional probiotics and their limitations and highlight the latest developments in the design and construction of probiotics as living diagnostics and therapeutics for the detection and treatment of a series of diseases, including pathogen infections, cancer, intestinal inflammation, metabolic disorders, vaccine delivery, cognitive health, and fatty liver. Besides we discuss the concerns regarding engineered probiotics and corresponding countermeasures and outline the desired features in the future development of engineered live biotherapeutics.

Citing Articles

Heterologous Expression of the Antiviral Lectin Griffithsin in Probiotic and In Vitro Characterization of Its Properties.

Tang J, Li R, Jiang T, Lv J, Jiang Y, Zhou X Microorganisms. 2025; 12(12.

PMID: 39770617 PMC: 11678560. DOI: 10.3390/microorganisms12122414.


Engineering Probiotics for Diabetes Management: Advances, Challenges, and Future Directions in Translational Microbiology.

Zhang S, Ma J, Ma Y, Yi J, Wang B, Wang H Int J Nanomedicine. 2024; 19:10917-10940.

PMID: 39493275 PMC: 11530765. DOI: 10.2147/IJN.S492651.


Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products.

Kim D, Lee S, Lee J, Whon T, Lee J, Jeon C Gut Microbes. 2024; 16(1):2412376.

PMID: 39377231 PMC: 11469438. DOI: 10.1080/19490976.2024.2412376.


A nuclease domain fused to the Snf2 helicase confers antiphage defence in coral-associated Halomonas meridiana.

Liu T, Gao X, Chen R, Tang K, Liu Z, Wang P Microb Biotechnol. 2024; 17(7):e14524.

PMID: 38980956 PMC: 11232893. DOI: 10.1111/1751-7915.14524.


Microbial metabolites are involved in tumorigenesis and development by regulating immune responses.

Liu J, Tian R, Sun C, Guo Y, Dong L, Li Y Front Immunol. 2024; 14:1290414.

PMID: 38169949 PMC: 10758836. DOI: 10.3389/fimmu.2023.1290414.